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episodes in some patients.2 Angiogenesis plays an
important role in tumor growth3 and is controlled and
maintained by several kinds of angiogenic factors in
many solid tumors.4 Vascular endothelial growth factor
C ardiac myxoma is an endocardial neoplasm thatarises from multipotential mesenchymal cells.1 This
tumor generally appears to grow rather quickly and
causes hemodynamic derangement and embolic
Objective: To clarify the association between angiogenesis and the clini-
copathologic features in cardiac myxoma, vascular endothelial growth
factor expression in the myxoma was examined by using reverse tran-
scriptase polymerase chain reaction and immunohistochemistry, and
the microvessel density was determined by counting microvessels in the
myxoma by using immunostaining for platelet endothelial cell adhesion
molecule 1. Methods: Seven fresh-frozen and 15 formalin-embedded tis-
sues were analyzed by means of reverse transcriptase polymerase chain
reaction and immunostaining for vascular endothelial growth factor,
respectively. The microvessel density was measured in the 15 formalin-
embedded tissues. Furthermore, immunostaining for proliferating cell
nuclear antigen was performed, and the proliferating cell nuclear anti-
gen–labeling index was calculated. Results: All of the 7 analyzed myxo-
mas were positive for vascular endothelial growth factor messenger
RNA, as determined by means of reverse transcriptase polymerase
chain reaction, whereas atrial septum and atrium tissues were negative.
Positive immunohistochemical reaction for vascular endothelial growth
factor was observed in the cells of all 15 myxomas. The size of myxomas
with high vascular endothelial growth factor expression was smaller
than that of myxomas with low vascular endothelial growth factor
expression. The microvessel density in myxomas with high vascular
endothelial growth factor expression was higher than that in myxomas
with low vascular endothelial growth factor expression. There was an
inverse correlation between the tumor size and the ratio of the microves-
sel density in the central part to the microvessel density in the peripher-
al part of myxomas. Furthermore, there was an inverse correlation
between the proliferating cell nuclear antigen–labeling index and the
tumor size, and the prolferating cell nuclear antigen–labeling index in
myxomas with high vascular endothelial growth factor expression was
higher than that in myxomas with low vascular endothelial growth fac-
tor expression. Conclusions: Cardiac myxomas produce vascular
endothelial growth factor, which probably induces angiogenesis for
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(VEGF) is an angiogenic factor that stimulates growth
of endothelial cells5,6 and is a major angiogenic factor
in several solid tumors.6 In the stroma of cardiac myx-
oma, microvessels are frequently observed histologi-
cally, and angiography shows that tumor vessels are
supplied from branches of the coronary arteries.7
However, angiogenesis in cardiac myxoma is not yet
well understood.
In this study VEGF expression of cardiac myxoma
was examined by using reverse transcriptase poly-
merase chain reaction (RT-PCR) and immunohisto-
chemistry, microvessel density was determined by
counting the microvessels in cardiac myxoma by using
immunostaining for platelet endothelial cell adhesion
molecule–1 (PECAM-1),8 and proliferating cell nuclear
antigen (PCNA) immunostaining was performed to
clarify the association between angiogenesis and the
clinicopathologic features of cardiac myxoma.
Methods
Patients and tissue preparation. Tissue samples of car-
diac myxoma were obtained from 15 patients who underwent
cardiac surgery between 1988 and 1998 in the Second
Department of Surgery, Shinshu University Hospital, and
affilliated hospitals. The clinicopathologic features of the
patients with cardiac myxoma are summarized in Table I. The
tumor size was defined as the largest diameter of the tumor.
Macroscopic findings were classified into 3 types: smooth
type, myxoid type, and friable type.9 Fresh samples about 8 ×
8 × 8 mm were collected from 7 of the 15 resected myxomas.
The myxoma tissues were immersed in liquid nitrogen imme-
diately after resection and then were stored frozen at –80°C.
The resected myxomas taken from the 15 patients were fixed
in 10% formalin buffered with phosphate at pH 7.4 and
embedded in paraffin. Serial sections were made and mount-
ed on glass slides. Hematoxylin-eosin staining was per-
formed to confirm the diagnosis of the tumors as myxoma.
RT-PCR for VEGF. Seven myxomas and 2 atrial septum
and 2 atrium tissues (as controls) were investigated by using
RT-PCR for VEGF. Total RNA was isolated as described by
Chomczynski and Sacchi.10 For reverse transcription to com-
plementary (c)DNA, 4 µg of total RNA was used. RNA was
denatured for 5 minutes at 99°C and then reverse transcribed
by incubation for 15 minutes at 42°C in the presence of 25
mmol/L MgCl2; 10× PCR Buffer II; random hexamer; diethyl
pyrocarbonate–treated, autoclaved, deionized, ultrafiltered
water; RNase inhibitor; and murine leukemia virus reverse
transcriptase (Perkin Elmer Cetus, Norwalk, Conn). PCR was
performed with 3 µL of cDNA in a final reaction volume of
15 µL. The assay mix contained diethyl pyrocarbonate–treat-
ed autoclaved, deionized, ultrafiltered water; 10× PCR Buffer
II; 25 mmol/L MgCl2; 10 pmol/L of the respective primers;
and 2.5 U of Taq DNA polymerase (Perkin Elmer Cetus). The
VEGF primers were provided by Dr H. A. Weich
(Braunschweig, Germany), and glyceraldehyde-phosphate
dehydrogenase primers were obtained from JCRB (Tokyo,
Japan). The conditions consisted of denaturation at 95°C for
10 minutes, 35 cycles of annealing at 94°C for 30 seconds,
and extension at 60°C for 30 seconds. The PCR products
were analyzed by means of electrophoresis on 5% polyacry-
lamide gels, stained with ethidium bromide, and pho-
tographed under UV light.
Immunostaining for VEGF. Fifteen myxomas and 2 atri-
al septum and 2 atrium tissues (as controls) were investigated
by means of VEGF immunostaining. The avidin-biotin com-
plex (ABC) method was used for VEGF immunostaining.
After deparaffinization with xylene, the sections were trans-
ferred to water through a graded series of ethanol and treated
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Table I. The clinicopathologic features of patients with cardiac myxoma
Patient Age Size Serum CRP Macroscopic 
No. (y) Sex Location Symptom (mm) (mg/dL) findings
1 45 F LA Cerebral embolism 33 0.21 Smooth
2 66 F LA Left hemiplegia 55 2.51 Smooth
3 51 F LA Palpitation, dyspnea 60 2.37 Myxoid
4 68 F LA PVC on ECG 70 1.62 Friable
5 61 M RA SOB 85 0.50 Smooth
6 62 F LA SOB 50 0.30 Smooth
7 68 F LA DOE 45 0.64 Smooth
8 68 F LA DOE 50 2.10 Smooth
9 36 F RA DOE 70 1.10 Myxoid
10 70 F LA Palpitation 50 — Myxoid
11 86 M LA Left hemiplegia 58 0.12 Friable
12 70 M LA SOB, cough 60 — Myxoid
13 72 F LA Dermatomyositis 34 0.72 Myxoid
14 20 M LA Chest pain 80 2.80 Myxoid
15 68 M LA Cerebral infarction 55 — Myxoid
CRP, C-reactive protein; LA, Left atrium; RA, right atrium; PVC, premature ventricular contraction; ECG, electrocardiography; SOB, shortness of breath; DOE,
dyspnea on exertion.
as follows: incubation with 2% normal horse serum for 30
minutes, with mouse anti-human VEGF IgG monoclonal
antibody (R11; Immuno-Biological Laboratories, Fujioka,
Japan) diluted 250-fold for 120 minutes and horse biotinylat-
ed anti-mouse IgG antibodies (Vector Laboratories, Inc,
Burlingame, Calif) diluted 200-fold for 60 minutes. Avidin-
biotinylated peroxidase complex (Vector Laboratories) was
used to treat the sections for 60 minutes. To dilute the anti-
bodies, 20 mmol/L sodium phosphate containing 0.15 mol/L
sodium chloride at pH 7.4 was used. After incubation in the
antibody solutions, the sections were incubated in a solution
of 0.05% 3,3´-diaminobenzidine tetrachloride (DAB) and
0.01% hydrogen peroxide in 50 mmol/L Tris-hydrochloric
acid (pH 7.2) for 10 minutes and then counterstained with 1%
methyl green stain. Normal mouse IgG was used for the pri-
mary antibody as a negative control.
Staining results were scored from + to ++++ on the basis of
the percentage of the myxoma cells showing positive staining
for VEGF. Scores were based on the following scale: ++++,
over 86% of the myxoma cells showed positive staining; +++,
61% to 85% of the myxoma cells showed positive staining;
++, 31% to 60% of the myxoma cells showed positive stain-
ing; and +, 0% to 30% of the myxoma cells showed positive
staining. The tumors were then classified into 2 groups; the
high-VEGF expression group showed positive reactions of
+++ or ++++, and the low-VEGF expression group showed
positive reactions of + or ++.
Immunostaining for PECAM-1 and measurement of
microvessel density. Immunostaining of PECAM-1 was per-
formed by using the ABC method with monoclonal antibody
JC70 (Dako Patts, Glostrup, Denmark), which recognizes
PECAM-1, diluted 500-fold. Sections immersed in 10
mmol/L citrate buffer were treated in a microwave oven
before staining. The number of microvessels was counted
according to the method of Maeda and colleagues.11 The
PECAM-1–stained sections were screened at 5-fold magnifi-
cation under a microscope to identify the areas of highest vas-
cular density within the whole area of myxoma tissue.
Microvessels in myxomas were counted in the 6 areas with
the highest density at 200-fold magnification. Microvessel
density in the whole area of myxoma tissue was then
expressed as the average of the microvessel count in these
areas. Furthermore, to investigate the distribution of the
microvessels in myxomas, the cut surface of the tumor was
divided into 2 areas; the peripheral part was defined as an out-
side quarter, and the central part was defined as the remain-
ing part. Microvessel density in the central part of the myxo-
ma tissue and microvessel density in the peripheral part were
measured by the same procedure used for microvessel densi-
ty in the whole area in each respective portion. Then the ratio
of the microvessel density in the central part to the microves-
sel density in the peripheral part was calculated.
PCNA immunostaining and measurement of PCNA-
labeling index. Immunostaining of PCNA was performed by
using the ABC method with monoclonal antibody PC10
(Dako Patts) diluted 100-fold. Serial sections adjacent to
those stained for VEGF were immunostained for PCNA.
Among the uniformly stained fields, 6 or 7 photomicrographs
were randomly taken from each section for quantifying the
number of PCNA-positive nuclei. Seventy or 80 myxoma
cells were counted in each photograph, and about 500 cells
from each specimen were thus evaluated. A dark accumula-
tion of DAB in the nuclei was judged to indicate a positive
reaction. The rate of PCNA-positive nuclei was calculated for
each section on the basis of about 500 myxoma cells (PCNA-
labeling index). The judgement of PCNA-positive nuclei
could be made in most cases but was difficult in some myxo-
ma cells of a few patients. When there were no apparent dif-
ferences with regard to the staining intensity between the
nucleus and cytoplasm, the myxoma cells were judged to be
negative.
Statistical analysis. The clinicopathologic features and
histochemical results were analyzed by using the Mann-
Whitney test or the χ2 test. The Pearson correlation coeffi-
cient was determined for the analysis of the relationship
between tumor size and microvessel density and between
microvessel density and PCNA-labeling index.
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Fig 1. RT-PCR for VEGF of the 7 cardiac myxomas. Lanes 1 to 7 were positive for VEGF-mRNA; lanes A and
AS were negative. Lanes 1-7, Patients 1, 2, 4, 5, 6, 7, and 8, respectively. AS, Atrial septum; A, atrium; GAPDH,
glyceraldehyde-phosphate dehydrogenase.
Results
RT-PCR for VEGF. RT-PCR for VEGF of the 7
myxomas is shown in Fig 1. All of the 7 tumors were
positive for VEGF messenger (m) RNA, whereas the 2
atrial septum and 2 atrial tissues were negative.
Immunostaining for VEGF. In cardiac myxoma
(Fig 2, A), a positive immunoreaction for VEGF was
observed as a dark accumulation of DAB reaction prod-
ucts in the cytoplasm of the tumor cells (Fig 2, B). In
all 15 tumors, tumor cells in the myxoma were stained
and then scored. Among the myxoma specimens, 4
were scored ++++, 4 were scored +++, 4 were secored
++, and 3 were scored +. There were thus 8 in the high-
VEGF expression group and 7 in the low-VEGF
expression group. In the atrial septum and atrial tissues
no positive immunoreaction for VEGF was observed.
The relationships between VEGF expression and the
clinicopathologic features were then investigated. The
mean age of the patients did not differ between the
high-VEGF expression group and the low-VEGF
expression group (61.6 ± 13.4 years vs 59.7 ± 20.5
years; P = .7), and the mean serum C-reactive protein
in the patients did not differ between the high-VEGF
expression group and the low-VEGF expression group
(1.22 ± 0.9 mg/dL vs 1.29 ± 1.14 mg/dL; P = .9). No
other variables, including sex of the patients, location,
and macroscopic findings of the myxoma, differed sig-
nificantly between the high-VEGF expression group
and the low-VEGF expression group. However, the
tumor size of the high-VEGF expression group was
smaller than that of the low-VEGF expression group
(49.0 ± 12.0 mm vs 66.1 ± 12.7 mm; P = .02).
Measurement of microvessel density. A positive
reaction for PECAM-1 was observed as a dark accu-
mulation of DAB reaction products in the vascular
endothelial cells in the cardiac myxoma (Fig 2, C).
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Fig 2. Immunostaining of VEGF, PECAM-1 and PCNA. A, Hematoxylin-eosin staining and B, VEGF staining:
a positive immunoreaction for VEGF was observed as a dark accumulation of DAB reaction products in the cyto-
plasm of the tumor cells (arrows). This tumor was scored ++++. C, PECAM-1 staining. A positive reaction for
PECAM-1 was observed as a dark accumulation of DAB reaction products in the vascular endothelial cells in car-
diac myxoma, but staining of myxoma cells was rarely observed. D, PCNA staining. A positive reaction for
PCNA was observed as a dark accumulation of DAB reaction products in the myxoma cells.
Myxoma cells were occasionally stained for PECAM-
1. Blood vessels were judged as circle formations of
endothelial cells stained by PECAM-1 immunostaining
and frequently included red blood cells. Under micro-
scopic observation, in large myxomas microvessels
were more frequently observed in the peripheral part
than in the central part of the tumors. The microvessel
density varied from 9.6 to 24.8 (18.8 ± 5.4, means ±
SD), and the ratio of the microvessel density in the cen-
tral part to the microvessel density in the peripheral
part varied from 0.54 to 1.40 (0.91 ± 0.31). There were
no significant correlations between microvessel densi-
ty and any of the clinicopathologic features.
Regarding the relationship between the microvessel
density and VEGF expression in cardiac myxoma, the
microvessel density in the high-VEGF expression
group was higher than that in the low-VEGF expres-
sion group (22.2 ± 2.6 vs 15.0 ± 5.2; P = .01; Fig 3, A).
The relationship between microvessel density and the
tumor size was then investigated. There was a weak but
nonsignificant correlation between the tumor size and
microvessel density (r = –0.29; P = .3; Fig 4, A). There
was a significant inverse correlation between the tumor
size and the ratio of the microvessel density in the cen-
tral part to the microvessel density in the peripheral
part (r = –0.53, P = .04; Fig 4, B).
Measurement of the PCNA-labeling index. A pos-
itive reaction for PCNA was observed in nuclei, which
was characterized as a dark accumulation of DAB reac-
tion products. PCNA-positive myxoma cells were dis-
tributed at random in the myxoma tissue (Fig 2, D).
The PCNA-labeling index varied from 0% to 52.5%
(21.6% ± 17.2%, mean ± SD) in the 15 myxomas. The
PCNA-labeling index in the high-VEGF expression
group was higher than that in the low-VEGF expres-
sion group (33.0% ± 15.0% vs 8.6% ± 7.6%; P = .01;
Fig 3, B). In addition, there was a weak correlation
between the PCNA-labeling index and microvessel
density (r = 0.50; P = .06; Fig 5, A). Furthermore, there
was an inverse correlation between the PCNA-labeling
index and the tumor size (r = –0.66, P = .01; Fig 5, B).
Discussion
Many studies have shown that tumors depend on
angiogenesis for their growth and metastasis.3 It is gen-
erally assumed that microvessel formation in or around
the tumor is stimulated by angiogenic factors,4 such as
VEGF secreted by tumor cells. VEGF plays an impor-
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Fig 3. The relationship between VEGF expression and microvessel density or PCNA-labeling index. A, The rela-
tionship between microvessel density and VEGF expression in cardiac myxoma showed that the microvessel den-
sity in myxomas with high VEGF expression was higher than that in myxomas with low VEGF expression. B,
The relationship between PCNA-labeling index and VEGF expression in cardiac myxoma showed that the
PCNA-labeling index in the high-VEGF expression group was higher than that in the low-VEGF expression
group.
A B
tant role in angiogenesis by increasing the permeabili-
ty of microvessels12 and by stimulating the selective
mitosis of vascular endothelial cells.6,13 We analyzed
the gene expression of VEGF in cardiac myxoma. All
of the resected myxomas were positive for VEGF
mRNA, whereas atrial tissues were negative for VEGF
mRNA. In the immunohistochemical analysis a posi-
tive reaction for VEGF was observed in myxoma cells
of all the resected patients. Previous studies have
shown that VEGF expression was markedly increased
in tumor cells compared with adjacent normal tissues in
several types of tumors, such as those found in breast
cancer.14,15 In this study a similar result was found in
cardiac myxomas. Therefore in cardiac myxoma it is
considered that VEGF is mainly expressed in the myx-
oma cells.
A significant correlation between microvessel densi-
ty and VEGF expression has been reported in clinical
specimens of several tumors.16,17 Similarly, in this
study microvessel density in the high-VEGF expres-
sion group was higher than that in the low-VEGF
expression group. Therefore the fact that cardiac myx-
oma with high expression of VEGF showed a high den-
sity of vascularity may indicate that VEGF plays a key
role in angiogenesis for this tumor. In malignant
tumors the tumor cells produce several angiogenic fac-
tors, and these angiogenic factors induce neovascular-
ization, which then enhances tumor growth. This con-
cept is known as the autocrine effect of angiogenic
factors for tumor cells. It is hypothesized that cardiac
myxoma may have such an autocrine system regulating
angiogenesis and tumor growth.
Concerning clinicopathologic features, in malignant
tumors, including those found in breast14 and gastroin-
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Fig 5. The relationship between PCNA-labeling index and microvessel density or tumor size. A, There was a
weak correlation between PCNA-labeling index and microvessel density. B, There was an inverse correlation
between PCNA-labeling index and tumor size.
A B
Fig 4. The relationship between microvessel density and tumor size. A, There was a weak correlation between
the microvessel density and tumor size. B, There was an inverse correlation between the ratio of the microvessel
density in the central part to the microvessel density in the peripheral part of the cardiac myxoma and tumor size.
A B
testinal cancers,15 it is reported that VEGF expression
and microvessel density are correlated with the growth
in size and clinical aggressiveness of the tumors. With
regard to the tumor size of cardiac myxoma, the size in
the high-VEGF expression group was smaller than that
in the low-VEGF expression group, and microvessel
density in large tumors was relatively lower than that in
small tumors. Furthermore, in large tumors microves-
sels were frequently observed in the peripheral part
compared with the central part of the myxoma.
Therefore in cardiac myxoma it is speculated that
angiogenesis frequently occurs in the central part of the
tumor in the early stages of tumor growth, whereas it
frequently occurs in the peripheral part of the tumor as
it grows larger. In addition, it is speculated that abun-
dant vascular supply in the peripheral part of the tumor
is necessary for its growth. Although angiogenesis is
important for the growth of cardiac myxoma, the role
of angiogenesis in cardiac myxoma may be different
from that in malignant tumors. The specific growth
conditions of myxomas in the cardiac chamber may
affect their angiogenesis.
PCNA has been recognized as an auxiliary protein for
DNA polymerase-delta and as an endogenous histologic
marker for the late G1/S phase in the cell cycle18 and
therefore has been used for investigating cell prolifera-
tion in solid tumors.19 To clarify the association between
angiogenesis and cell proliferation in cardiac myxoma,
relationships between VEGF expression and PCNA-
labeling index or microvessel density and PCNA-label-
ing index were additionally investigated. The PCNA-
labeling index was high in small myxomas with both
high microvessel density and high VEGF expression.
Namely, small cardiac myxomas in the early stage of
tumor growth may show high proliferative activity, and
angiogenesis induced by VEGF (probably secreted by
myxoma cells) may be needed for the tumor growth.
In conclusion, cardiac myxomas produce VEGF,
which probably contributes to inducing angiogenesis
for the tumor growth, especially in the early stage.
We thank Professor S. Murase for his assistance with sta-
tistical analysis.
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